Skip to content


  • Research article
  • Open Access
  • Open Peer Review

AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1Email author,
  • 2 and
  • 1
Contributed equally
BMC Cancer201212:129

  • Received: 4 October 2011
  • Accepted: 30 March 2012
  • Published:
Open Peer Review reports



Angiogenesis plays an important role in tumor growth and metastasis, therefore antiangiogenic therapy was widely investigated as a promising approach for cancer therapy. Recently, pigment epithelium-derived factor (PEDF) has been shown to be the most potent inhibitor of angiogenesis. Adeno-associated virus (AAV) vectors have been intensively studied due to their wide tropisms, nonpathogenicity, and long-term transgene expression in vivo. The objective of this work was to evaluate the ability of AAV-mediated human PEDF (hPEDF) as a potent tumor suppressor and a potential candidate for cancer gene therapy.


Recombinant AAV2 encoding hPEDF (rAAV2-hPEDF) was constructed and produced, and then was assigned for in vitro and in vivo experiments. Conditioned medium from cells infected with rAAV2-hPEDF was used for cell proliferation and tube formation tests of human umbilical vein endothelial cells (HUVECs). Subsequently, colorectal peritoneal carcinomatosis (CRPC) mouse model was established and treated with rAAV2-hPEDF. Therapeutic efficacy of rAAV2-hPEDF were investigated, including tumor growth and metastasis, survival time, microvessel density (MVD) and apoptosis index of tumor tissues, and hPEDF levels in serum and ascites.


rAAV2-hPEDF was successfully constructed, and transmission electron microscope (TEM) showed that rAAV2-hPEDF particles were non-enveloped icosahedral shape with a diameter of approximately 20 nm. rAAV2-hPEDF-infected cells expressed hPEDF protein, and the conditioned medium from infected cells inhibited proliferation and tube-formation of HUVECs in vitro. Furthermore, in CRPC mouse model, rAAV2-hPEDF significantly suppressed tumor growth and metastasis, and prolonged survival time of treated mice. Immunofluorescence studies indicated that rAAV2-hPEDF could inhibit angiogenesis and induce apoptosis in tumor tissues. Besides, hPEDF levels in serum and ascites of rAAV2-hPEDF-treated mice were significant higher than those in rAAV2-null or normal saline (NS) groups.


Thus, our results suggest that rAAV2-hPEDF may be a potential candidate as an antiangiogenic therapy agent.


  • AAV
  • PEDF
  • Tumor
  • Antiangiogesis
  • Gene therapy


Cancer is a major public health problem in the world and causes millions of death each year. More than 1.5 million new cancer cases and 560,000 deaths from cancer are projected to occur in 2010 in the USA [1]. Surgical resection, chemotherapy, and radiotherapy are conventional therapeutic strategies, which were widely used in clinic. Unfortunately, surgical resection is not sufficiently effective for advanced cancer, and chemotherapy and radiotherapy always induce severe side effects [2, 3]. Obviously, it is necessary to develop novel therapeutic strategies to optimize available non-surgical approaches. Gene therapy was proposed as a new approach to eradicate malignant cells, which may be beneficial to cancer patients at all stages [4].

Both tumor growth and systemic metastasis are highly dependent on angiogenesis [5]. Tumor less than 1 mm3 could receive necessary nutrients and oxygen through diffusion, however, a tumor is unable to grow above approximate 1 mm3 without neovascularization [6]. Angiogenesis is a complex multistep process consisting of proliferation and migration of endothelial cells, degeneration of basement membrane, and formation of new lumen, which is tightly regulated by both positive and negative factors [7]. Microvascularity of normal tissue is regulated by the proangiogenic and antiangiogenic factors to maintain a quiescent state. Tumor growth and metastasis require neovascularization, therefore, tumors use various mechanisms to shift the balance to an angiogenic inductive environment. In this process, overexpression of proangiogenic factors is accompanied by down regulation of antiangiogenic factors [8]. As angiogenesis is essential for tumor growth and metastasis, antiangiogenesis has been proposed as a therapeutic strategy for cancer treatment [9].

Pigment epithelium-derived factor (PEDF), a 50-kDa secreted glycoprotein, is a member of the serpin superfamily of serine protease inhibitors, which was first identified in a conditioned medium of cultured primary human fetal retinal pigment epithelial cells [10]. To data, it was found that PEDF is widely expressed in human tissues and is involved in many physiological and pathological processes [11]. PEDF is a multifunctional protein and proved to be neurotrophic, neuroprotective, and antiangiogenic. And PEDF has recently been shown to be a more potent inhibitor of angiogenesis than other endogenous angiogenic inhibitors, including angiostatin, endostatin, and thrombospondin-1 [12, 13]. Antiangiogenic activity of PEDF was associated with induction of endothelial cell apoptosis via the Fas/FasL death pathway and down-regulation of vascular endothelial growth factor (VEGF) expression. Previous works suggested that PEDF is a potential tumor suppressor [6, 1417].

Although gene therapy is an effective way to treat cancers and many other chronic diseases, the safety and efficacy of gene therapy depends on the development of safe and effective delivery systems [1823]. The recombinant adeno-associated virus (rAAV) vectors appear to be the promising potential candidate as safe and effective delivery system for gene therapy due to its attractive features [2427]. rAAV vectors show low immunogenicity and ability to infect both dividing and nondividing cells. Besides, rAAV can maintain long-term undiminished transgene expression in vivo. The most important, rAAV vectors are nonpathogenic, which are not associated with any known human diseases. Until now, several different serotypes of AAV have been identified by serological analysis [2830], among which rAAV serotype 2 vectors (rAAV2) are mostly studied and used in animal experiments and clinical trials [31, 32]. Most of the previous studies about rAAV-mediated gene transfer of PEDF mainly focused on eye diseases, however, rAAV-mediated gene transfer of PEDF for tumor treatment is rarely reported.

According to the BLAST analysis, the homology between human PEDF and mouse PEDF is very high. Besides, several previous contributions suggested that hPEDF was effective on mouse tumor models. Therefore, in this work, we constructed rAAV2 encoding human PEDF (rAAV2-hPEDF) and investigated its anti-tumor efficacy in colorectal peritoneal carcinomatosis (CRPC) mouse model. Our results demonstrated that rAAV2-hPEDF may be a potent tumor inhibitor and a potential candidate for cancer gene therapy.


Cell lines and animals

CT26 cells (murine colon carcinoma cell line) were purchased from the American Type Culture Collection (ATCC, Rockville, MD) and cultured in RPMI1640 medium (GIBCO, USA) containing 10% fetal bovine serum (FBS, GIBCO, USA) and 1% penicillin/streptomycin. Primary HUVECs were isolated from human umbilical cord veins by a standard procedure [33], and grew in Dulbecco's Modified Eagle's medium (DMEM, GIBCO, USA) supplemented with 20% fetal bovine serum (FBS, GIBCO, USA)and basic fibroblast growth factor (bFGF, 10 ng/ml). HUVECs at passages 2 to 3 were used for experiments. All above cells were maintained at 37°°C in a humidified incubator containing 5% CO2.

BALB/c mice weighing 20 to 22 g were purchased from the Laboratory Animal Center of Sichuan University and housed at controlled temperature of 20-22°°C, relative humidity of 50-60% and 12 h light-dark cycles. Animals were provided with standard laboratory chow and tap water ad libitum. All the animals would be in quarantine for a week before treatment. All animal procedures were performed following the protocol approved by the Institutional Animal Care and Treatment Committee of Sichuan University (Chengdu, P.R. China). All mice were treated humanely throughout the experimental period.

rAAV vector construction and production

According to standard cloning techniques, the human PEDF (hPEDF) cDNA was amplified from pBLAST49-hPEDF template (stored by State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China) using the designed primers (the upstream primer: 5'-GGAATTCATGCAGGCCCTGGTGCTACTC-3'; the downstream primer: 5'-ACGCGTCGACTTAGGGGCCCCTGGGGTC-3'), and then inserted into pAAV2 expression vector (provided by Dr. Wu XB, State Key Laboratory for Molecular Virology and Genetic Engineering, Beijing, China) to form the new plasmid, pAAV2-hPEDF (Figure 1A). The control plasmid pAAV2-null was constructed in the similar manner (Figure 1A). Packaging and purification of rAAV particles were done as descried previously [34]. The morphological characteristics of rAAV2-hPEDF particles were examined by transmission electron microscope (TEM, H-6009IV, Hitachi, Tokyo, Japan). The titers of rAAV2-hPEDF and rAAV2-null measured by dot blot DNA analysis were 4 × 1012 v.g./mL and 1 × 1012 v.g./mL, respectively. All viruses prepared in this study were stored at 4°°C in PBS before use.
Figure 1
Figure 1

Construction scheme and characterization of rAAV 2 -hPEDF. A: Construction scheme of rAAV2-hPEDF and control vector rAAV2-null; B: TEM image of rAAV2-hPEDF particles; C: Expression of hPEDF in rAAV2-hPEDF infected CT26 cells.

rAAV2-hPEDF infection assay

Approximately 2 × 105 CT26 cells were plated into 6-well plates in complete medium and allowed to attach for 24 hours. Subsequently, cells were gently washed with PBS, and then rAAV2-hPEDF or rAAV2-null was applied to cells at MOI (multiplicity of infection) of 105 v.g. per cell in serum-free medium, with normal saline (NS) as non-infection control. After incubation for 6 hours, complete medium with 10% FBS was added to each well. Then, the conditioned medium was collected after further culture for 72 hours for western blotting analysis and cell proliferation assay.

Western blotting analysis

Conditioned media from CT26 cells infected with rAAV2-hPEDF, rAAV2-null or NS were used for Western blotting analysis. Concentrations of protein were determined using a modified Lowry protein assay kit (ThermoScientific), and an equal amount of protein (40 μg) from each sample was loaded on to 10% SDS-PAGE gel followed by transfer to a nitrocellulose membrane sheet, probed for anti-PEDF (1:500, upstates, Lake Placid, USA). The membranes were washed, and blots were developed with horseradish peroxidase (HRP)-conjugated secondary antibodies. The protein bands were detected using an enhanced chemiluminescence (ECL) detection system. (Pierce, Rockford, Illinois, USA).

Cell proliferation assay

Cell proliferation assay was conducted using 3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (methyl thiazolyl tetrazolium, MTT) method to determine the effect of hPEDF derived from rAAV2-hPEDF infected cells on HUVECs. HUVECs were plated at a density of 1 × 104 cells per well in 100 μL of medium in 96-well plates and grown for 48 hours. The conditioned media from CT26 cells infected with rAAV2-hPEDF, rAAV2-null, or NS were collected as described above, and each supernatant was two-fold serially diluted and added to each well in triplicate. After 48 hours of incubation, viability of cells was measured using MTT method. The mean percentage of cell survival relative to that of untreated cells was estimated from data from three individual experiments, and all data were expressed as the mean value ± standard deviation (S.D.).

Endothelial cell capillary-like tube formation assay

Tube formation assay was conducted as previously described [35]. Briefly, prechilled Matrigel was pipetted into prechilled 24-well plates and polymerized at 37°°C for 30 minutes. Then, HUVECs suspended in complete medium were seeded onto the Matrigel, and they were treated with conditioned medium form cells infected with NS, rAAV2-null, or rAAV2-hPEDF, respectively. After 6 hours of incubation, the endothelial cells were photographed with a digital camera attached to an inverted microscope. Three independent experiments were performed.

Animal model and treat plan

CRPC mouse model was established and subsequently treated. Briefly, the mice were intraperitoneally injected with 200 μl of cell suspension containing 5 × 105 CT26 cells. Tumors were allowed to grow for 3 days. Tumor-bearing mice were randomly assigned to one of the following groups (n = 12 mice per group): NS, rAAV2-null (2 × 1010 v.g. per mouse), and rAAV2-hPEDF (2 × 1010 v.g. per mouse).

Treatments were administered through intraperitoneal injection with a single dose of 200 μl above mentioned viruses. For tumor growth inhibition study (6 mice per group), the number and weight of tumor nodes in each group were measured on day 18 after tumor cell inoculation. After day 18, NS and rAAV2-null-treated mice began to die. To further study the therapeutic effect against colorectal cancer, the survival time of mice treated with the protocols described above was observed (6 mice per group).

Detection of microvessel density (MVD)

The antiangiogenesis of rAAV2-hPEDF was determined by immunofluorescent analysis of neovascularization in tumor tissue as described [36]. Briefly, frozen sections of tumors were fixed in acetone, washed with PBS, stained with rat anti-mouse CD31 (platelet endothelial cell adhesion molecule-1) polyclonal antibody (1:50; BD Pharmingen™, USA), washed twice with PBS, and followed by incubation with a Rhodamine-conjugated second antibody (Abcam, USA). MVD was determined by counting the number of microvessels per high-power field in the sections with a fluorescence microscopy as described.

Quantitative assessment of apoptosis

Tumor sections were prepared as described above. Terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) staining was done using an in situ cell death detection kit (DeadEnd™ Fluorometric TUNEL System, Promega, Madison, USA) following the manufacturer's protocol. It is based on the enzymatic addition of digoxigenin-nucleotide to the nicked DNA by the recombinant terminal deoxynucleotidyl transferase (rTdT) [37]. In the tissue sections, four equal-sized fields were randomly chosen and analyzed. The apoptotic index was calculated as a ratio of the apoptotic cell number to the total tumor cell number in each high-power field.

Detection of hPEDF concentrations in serum and ascites

Quantitation of hPEDF expression in serum and ascites was determined by enzyme-linked immunosorbnent assay (ELISA). A commercial PEDF ELISA kit (ADL, Biotech. Dev. Co., USA) was used following the manufacturer's instructions. Briefly, pre-diluted serum or ascites were added to wells of the pre-coated ELISA plate and incubated for one hour. After washing, HRP-conjugated secondary antibody was added. Antibody binding was detected with substrate A and B. After the reaction was stopped with H2SO4, the absorbance at 450 nm was measured by an ELISA reader (Bio-Rad 680, USA).

Toxicity evaluation

To investigate potential toxicity or side effects of rAAV2-hPEDF, mice were observed continuously during the treatment process, including the general conditions (the activity, energy, hair, feces, behavior pattern, and other clinical signs), body weight, and mortality. For histopathological studies, samples were obtained from major organs including heart, liver, spleen, lungs, and kidneys. All the samples were fixed in 10% neutral-buffered formalin, and embedded in paraffin. Then, the tissues were sectioned and stained with hematoxylin and eosin (H&E).

Statistical analysis

The statistic analysis was carried out using SPSS 15.0 software (Chicago, IL, USA). Comparison of numbers of tumor nodes was performed using one-way analysis of variance (ANOVA). Survival curves were generated based on the Kaplan-Meier method and statistical significance was determined by Mann-Whitney U-tests. A P value < 0.05 on a 2-tailed test was considered statistically significant.


Expression of hPEDF in colonic cancer cells after rAAV-mediated gene transfer in vitro

rAAV2-hPEDF was successfully constructed (Figure 1A). TEM was used to determine the morphological characteristics of rAAV2-hPEDF particles. As presented in Figure 1B, rAAV2-hPEDF particles were non-enveloped icosahedral shape with a diameter of approximately 20 nm. To determine whether hPEDF could be secreted by rAAV2-hPEDF-infected cells, we analyzed the conditioned medium from CT26 cells infected in vitro with either rAAV2-hPEDF or control vector rAAV2-null by Western blotting analysis using a monoclonal antibody against hPEDF. As shown in Figure 1C, in the conditioned medium from rAAV2-hPEDF-infected cells, only one band with molecular weight of 50 kDa was observed, which coincided with the lane loaded with hPEDF protein. There was no hPEDF expression in the conditioned medium from the cells infected with control vector rAAV2-null or NS control. This result suggested that rAAV2-hPEDF could transfer hPEDF gene into cultured cells and produce secretory protein.

Biological activity of hPEDF produced by rAAV2-hPEDF in vitro

To evaluate the bioactivity of secreted hPEDF from CT26 cells infected with rAAV2-hPEDF, HUVEC proliferation assay and endothelial cell capillary-like tube formation assay were conducted.

For in vitro HUVEC proliferation assay, HUVECs were exposed to the conditioned media from CT26 cells infected with rAAV2-hPEDF, rAAV2-null, or NS, respectively. After 48 hours of incubation, viability of HUVECs was measured using MTT method. We found that incubation with the conditioned medium from CT26 cells infected with rAAV2-hPEDF significantly inhibited HUVEC proliferation compared with the conditioned media from cells infected with rAAV2-null or NS. According to Figure 2, the conditioned medium from cells infected with rAAV2-hPEDF inhibited HUVEC proliferation by 59.9 ± 8.1% at a 1:2 dilution concentration, and the inhibitory rate decrease with the increase of dilution concentration showing a dose-dependent effect. In contrast, the conditioned medium from rAAV2-null had no inhibitory effect on the proliferation of HUVECs.
Figure 2
Figure 2

Inhibitory effect of rAAV 2 -hPEDF on proliferation of HUVECs in vitro. Exponentially growing HUVECs were exposed to the conditioned medium from rAAV2-hPEDF, rAAV2-null, or NS infected CT26 cells for 72 hours. Percent inhibition was calculated by the MTT method. Columns, mean of three independent experiments; error bars, SD.

Although angiogenesis is a complex process of several kinds of cells, tube formation of endothelial cells is one of the key steps of angiogenesis. Two-dimensional Matrigel assay was used to examine the potential effects of conditioned media from cells infected with rAAV2-hPEDF, rAAV2-null, or NS on the capillary-like structure formation of endothelial cells, respectively. As shown in Figure 3, HUVECs seeded on the surface of Matrigel formed capillary-like structures in conditioned medium from NS or rAAV2-null group within 6 hours. However, treatment with the conditioned medium from cells infected with rAAV2-hPEDF strongly reduced the tube formation of endothelial cells (Figure 3D).
Figure 3
Figure 3

rAAV 2 -hPEDF inhibited tube formation of HUVECs. Representative photographs of HUVECs treated with the conditioned medium from NS (A), rAAV2-null (B), or rAAV2-hPEDF (C) infected CT26 cells, and inhibition ratio of tube formation (D). Columns, mean of three independent experiments; error bars, SD.

These results indicated that the hPEDF secreted by infected cells was highly bioactive and could block angiogenesis in vitro by inhibiting the proliferation and reducing the formation of tube-like structure of endothelial cells.

Inhibition of tumor growth and metastasis with rAAV2-hPEDF

To investigate the therapeutic effect of rAAV2-hPEDF, forty-eight CRPC mice were divided into three groups and treated with NS, rAAV2-null, or rAAV2-hPEDF, respectively. On day 18 after cell inoculation, mean number and weight of tumor nodes in rAAV2-hPEDF-treated group were dramatically decreased compared with those in rAAV2-null (P < 0.001 and P < 0.001, respectively) or NS group (P < 0.001 and P < 0.001, respectively) (Figure 4A and 4B). Besides, the size of tumor nodes in rAAV2-hPEDF-treated group was significantly smaller in comparison with control groups (Figure 4A). According to H&E staining of tumor in each group, less vessels and remarkable necrosis areas were observed in tumor tissues from rAAV2-hPEDF group (Figure 4A). These findings indicated rAAV2-hPEDF not only inhibits growth of implanted tumor, but also impairs tumor metastasis. Furthermore, there was a substantial increase in the life span of the rAAV2-hPEDF-treated mice, and the median survival of rAAV2-hPEDF group was 37 days versus 24 days or 25 days in rAAV2-null or NS group, respectively (Figure 4C). Besides, due to the inhibition of tumor growth and metastasis, body weight of mice in rAAV2-hPEDF-treated group increased slower compared with that in NS or rAAV2-null groups (Figure 4D). Mice were investigated in particular for potential side effects attributable to rAAV2-hPEDF therapy. No severe toxic effects were observed in gross measures, such as severe weight loss, changes in behavior, and feeding. Moreover, no histopathological changes were found in major organs including heart, liver, spleen, lungs, and kidneys (Figure 4E).
Figure 4
Figure 4

rAAV 2 -hPEDF inhibited growth and metastasis in CRPC model, and prolonged survival time of treated mice. A: Representative photographs and H&E staining of abdominal tumors in NS (a), rAAV2-null (b), and rAAV2-hPEDF (c) groups; B: Mean number and weight of tumor nodules in each group; C: Survival curves of mice in each group; D: Body weight of mice in each group; E: Photographs of major organs after intraperitoneal administration of rAAV2-hPEDF and NS (×400).

Inhibition of tumor angiogenesis

To better understand the mechanism by which treatment with rAAV2-hPEDF inhibited the tumor growth and metastasis, the MVD of each group was measured. Sections of tumor nodes from mice in all three treatment groups were stained for CD31 immunofluorescence to determine the MVD as a measure of tumor angiogenesis (Figure 5). As shown in Figure 5A to 5C, significant fewer immunoreactive microvessels were observed in tumor tissue from mice treated with rAAV2-hPEDF. According to Figure 5D, MVD of tumor tissues from rAAV2-hPEDF-treated mice (18.6 ± 4.7) was significant lower compared with control vessel rAAV2-null (49.6 ± 7.7, p < 0.001) or NS group (49.0 ± 8.7, p < 0.001).
Figure 5
Figure 5

CD31 immunofluorescent staining of tumor nodules. Representative CD31 immunofluorescent images of NS (A), rAAV2-null (B), and rAAV2-hPEDF (C) group, and mean MVD in each group.

Induction of tumor apoptosis

To explore the role of rAAV2-hPEDF on apoptosis of tumor cells, tumor resections were subjected to immunofluorescent TUNEL staining assays for respective determination of apoptotic index. As shown in Figure 6A to 6C, within a similar high-power field, more apoptotic cells (with green nuclei) in tumor tissues were observed in rAAV2-hPEDF-treated mice compared with those in rAAV2-null or NS group. The apoptosis index was significantly higher in rAAV2-hPEDF group (28.6% ± 5.0%) than in rAAV2-null (7.4% ± 2.9%, p < 0.001) or NS group (4.4% ± 1.5%, p < 0.001), respectively (Figure 6D).
Figure 6
Figure 6

TUNEL immunofluorescent staining of tumor nodules. Representative TUNEL immunofluorescent images of NS (A), rAAV2-null (B), and rAAV2-hPEDF (C) group, and mean apoptotic index in each group.

hPEDF concentrations in serum and ascites

To evaluate whether the suppression of tumor growth and metastasis and increase of life span in rAAV2-hPEDF-treated group is associated with the hPEDF expression, hPEDF concentrations in serum and ascites were measured in each treatment groups. Data in Figure 7 show the hPEDF levels in serum and ascites on day 18 after tumor cell inoculation. hPEDF levels in serum (21.87 ± 5.94 ng/mL) or ascites (42.23 ± 6.80 ng/mL) in rAAV2-hPEDF-treated group were significantly higher than those in rAAV2-null (3.03 ± 1.61 ng/mL in serum, P < 0.001; 3.95 ± 1.09 ng/mL in ascites, P < 0.001) or NS (3.83 ± 1.76 ng/mL in serum, P < 0.001; 3.57 ± 1.47 ng/mL in ascites, P < 0.001) group, respectively. Furthermore, in rAAV2-hPEDF-treated group, hPEDF level in ascites was significantly higher than that in serum (P < 0.001). The results indicated that intraperitoneal injection of rAAV2-hPEDF produced high level secretory hPEDF protein in mice, which inhibited the growth and metastasis of tumor.
Figure 7
Figure 7

hPEDF concentrations in serum and ascites at day 18 after tumor inoculation. hPEDF levels in serum and ascites of rAAV2-hPEDF-treated mice were significant higher than those in rAAV2-null (P < 0.001) or NS (P < 0.001) groups.


Colorectal carcinoma is one of the most frequent cancers, and is the third leading cause of cancer-associated deaths worldwide [7]. Besides liver metastasis and regional lymph nodes metastasis, peritoneal carcinomatosis of colon cancer occurs in 12-20% of patients whose disease recurs [38, 39]. However, therapeutic effects of conventional treatments, such as surgical resection, chemotherapy and radiotherapy, are not very encouraging. Therefore, unremitting efforts were focused on developing novel therapeutic strategies. Data presented in this study showed that AAV-mediated delivery of hPEDF could prevent tumor growth and metastasis and prolong the survival time in murine CRPC model (Figure 4A to 4D).

Angiogenesis is essential to maintain tumor growth and metastasis, therefore antiangiogenic therapy is a feasible approach for cancer therapy. In recent years, a variety of angiogenesis inhibitors have been discovered, among which PEDF is the most promising one. Based on previous studies, down-regulation of PEDF e was very prevalent in a range of tumors [11]. There are two major pathways by which PEDF exerts its antitumor effects: antiangiogenesis and apoptosis-mediated tumor suppression. In this study, we examined biological activity of hPEDF produced by rAAV2-hPEDF in vitro and in vivo. In HUVEC proliferation assay, the conditioned medium from cells infected with rAAV2-hPEDF inhibited HUVEC proliferation by 59.9 ± 8.1% at a 1:2 dilution concentration (Figure 2). In HUVEC tube formation assay, treatment with the conditioned medium from cells infected with rAAV2-hPEDF dramatically reduced the tube formation of HUVECs by 85.8% ± 4.7% (Figure 3). Furthermore, sections of tumors stained for CD31 immunofluorescence showed that the MVD of tumors in rAAV2-hPEDF-treated mice was reduced by 62.1 ± 9.6% compared with control group. In immunofluorescent TUNEL staining assay, the apoptosis index in rAAV2-hPEDF group increased by 6.5 times compared with NS group (Figure 6). Therefore, our in vitro and in vivo results suggested that suppression of tumor growth and metastasis by rAAV2-hPEDF was associated with the decreased MVD and induction of apoptosis in tumors.

Antiangiogenic therapy requires constant therapeutic levels of antiangiogenic factors in vivo to achieve its therapeutic effect, therefore recombinant proteins are limited for widespread clinical use [40]. It is because high therapeutic doses of recombinant proteins are needed, but resultant yield rates of recombinant proteins may be low due to denaturizing in purification process. Furthermore, owing to the short half-life of protein in vivo, maintaining therapeutically effective serum levels needs a frequent dosing regimen and high doses of expensive purified recombinant proteins. Thus, efforts should be made to develop effective and wide-applied strategy, and one potential solution for this is gene therapy. The key of successful gene therapy is gene delivery system. AAV, as one of the most promising viral vectors for human gene therapy, has many advantages compared to other viral vectors, such as non-pathogenicity, low immunogenicity, and long-term undiminished transgene expression in vivo. Since the first infectious clone of AAV2 was established in 1982, AAV2 vectors have gained increasing attention in gene therapy applications [41, 42]. AAV2 have been extensively investigated in preclinical studies for many diseases, including hemophilia, rheumatoid arthritis, cystic fibrosis, and etc [42, 43]. However, further studies suggested that most humans exposed to AAV2 would develop neutralizing antibodies to the vector, which hindered its transduction efficiency [44, 45]. Although the application of AAV2 hampers clinical potential of this approach, the use of well-studied AAV2 will provide preliminary proof of efficacy which would warrant future studies using vectors derived from other serotypes. In this study, we successfully constructed and produced rAAV2-hPEDF, and the titer of rAAV2-hPEDF was 4 × 1012 v.g./mL. Besides, the morphological characteristics of rAAV2-hPEDF were detected by TEM, which exhibited that rAAV2-hPEDF particles were non-enveloped icosahedral shape with a diameter of approximately 20 nm (Figure 1B). A single intraperitoneal administration of rAAV2-hPEDF resulted in suppression of tumor growth and metastasis in the CRPC mouse model with maximum inhibition of 75.85% (Figure 4B). Besides, our results indicated that a single intraperitoneal administration of rAAV2-hPEDF could increase hPEDF levels in serum and ascites for a long period (Figure 7), which could continue to inhibit angiogenesis in tumor. During the treatment process, no severe toxic effects were observed, and no histopathological changes were found in major organs (Figure 4E). All these data confirmed that AAV is a safe and efficient gene delivery vector.


In conclusion, our studies demonstrated that rAAV2-hPEDF could infect cells and produce secretory hPEDF protein, which was proved to be functional on inhibiting proliferation and tube-formation of HUVECs in vitro. Moreover, rAAV2-hPEDF significantly suppressed tumor growth and metastasis and prolonged survival time of treated mice in CRPC model. rAAV2-hPEDF could increase hPEDF levels in serum and ascites, inhibit angiogenesis, and induce apoptosis in tumor tissues. Therefore, our results indicated that rAAV2-hPEDF may be a potential candidate as an antiangiogenesis therapy agent for cancer gene therapy.




One-way analysis of variance


Basic fibroblast growth factor


Colorectal peritoneal carcinomatosis


Dulbecco's Modified Eagle's medium


Enhanced chemiluminescence


Enzyme-linked immunosorbnent assay


Fetal bovine serum


Human pigment epithelium-derived factor


Human umbilical vein endothelial cells


Hematoxylin and eosin




Methyl thiazolyl tetrazolium


Microvessel density


Normal saline


Pigment epithelium-derived factor


Recombinant adeno-associated virus


Recombinant adeno-associated virus serotype 2 vectors


Recombinant adeno-associated virus serotype 2 vectors encoding human pigment epithelium-derived factor


Standard deviation


Terminal deoxynucleotidyl transferase-mediated nick-end labeling


Vascular endothelial growth factor.



This study was funded by the National Key Basic Research Program (973 Program) of China (2010CB529900).

Authors’ Affiliations

State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, and School of Life Sciences, Sichuan University, Chengdu, 610041, P.R. China
Department of Gynecology and Obstetrics, Second West China Hospital, Sichuan University, Chengdu, 610041, P.R. China


  1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.PubMedGoogle Scholar
  2. Ozols RF, Bookman MA, Young RC: Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med. 2006, 354 (15): 1641-1643.PubMedGoogle Scholar
  3. Armstrong D, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J, Burger R: Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med. 2006, 354: 34-43. 10.1056/NEJMoa052985.PubMedGoogle Scholar
  4. Roth JA, Cristiano RJ: Gene therapy for cancer: What have we done and where are we going?. J Natl Cancer Inst. 1997, 89 (1): 21-10.1093/jnci/89.1.21.PubMedGoogle Scholar
  5. Hansen S, Grabau DA, Sørensen FB, Bak M, Vach W, Rose C: The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Canc Res. 2000, 6 (1): 139-Google Scholar
  6. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C: Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther. 2003, 8 (1): 72-79. 10.1016/S1525-0016(03)00128-X.PubMedGoogle Scholar
  7. Nie B, Shen Z, Wen JB, Wong OGW, Hsueh WD, Huo LF, Kung HF, Jiang B, Lin M: AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Mol Cancer Ther. 2008, 7 (9): 2855-10.1158/1535-7163.MCT-08-0366.PubMedGoogle Scholar
  8. Cai J, Parr C, Watkins G, Jiang WG, Boulton M: Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res. 2006, 12 (11): 3510-10.1158/1078-0432.CCR-06-0094.PubMedGoogle Scholar
  9. Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ: In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies* 1. J Thorac Cardiovasc Surg. 2003, 126 (1): 28-38. 10.1016/S0022-5223(02)73616-7.PubMedGoogle Scholar
  10. Becerra SP, Sagasti A, Spinella P, Notario V: Pigment epithelium-derived factor behaves like a noninhibitory serpin. J Biol Chem. 1995, 270 (43): 25992-10.1074/jbc.270.43.25992.PubMedGoogle Scholar
  11. Ek ETH, Dass CR, Choong PFM: Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Ther. 2006, 5 (7): 1641-10.1158/1535-7163.MCT-06-0107.PubMedGoogle Scholar
  12. Dawson D, Volpert O, Gillis P, Crawford S, Xu HJ, Benedict W, Bouck N: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999, 285 (5425): 245-10.1126/science.285.5425.245.PubMedGoogle Scholar
  13. Houenou LJ, D'Costa AP, Li L, Turgeon VL, Enyadike C, Alberdi E, Becerra SP: Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons. J Comp Neurol. 1999, 412 (3): 506-514. 10.1002/(SICI)1096-9861(19990927)412:3<506::AID-CNE9>3.0.CO;2-E.PubMedGoogle Scholar
  14. Hase R, Miyamoto M, Uehara H, Kadoya M, Ebihara Y, Murakami Y, Takahashi R, Mega S, Li L, Shichinohe T: Pigment Epithelium-Derived Factor Gene Therapy Inhibits Human Pancreatic Cancer in Mice. Clin Cancer Res. 2005, 11 (24): 8737-10.1158/1078-0432.CCR-05-1323.PubMedGoogle Scholar
  15. Streck CJ, Zhang Y, Zhou J, Ng C, Nathwani AC, Davidoff AM: Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg. 2005, 40 (1): 236-243. 10.1016/j.jpedsurg.2004.09.049.PubMedGoogle Scholar
  16. Yang H, Grossniklaus HE: Constitutive Overexpression of Pigment Epithelium-Derived Factor Inhibition of Ocular Melanoma Growth and Metastasis. Invest Ophthalmol Vis Sci. 2010, 51 (1): 28-10.1167/iovs.09-4138.PubMedPubMed CentralGoogle Scholar
  17. Yang LP, Cheng P, Peng XC, Shi HS, He WH, Cui FY, Luo ST, Wei YQ, Yang L: Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res. 2009, 28: 75-10.1186/1756-9966-28-75.PubMedPubMed CentralGoogle Scholar
  18. Cavazzana-Calvo M, Hacein-Bey S, Basile GS, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000, 288 (5466): 669-10.1126/science.288.5466.669.PubMedGoogle Scholar
  19. Blau H, Khavari P: Gene therapy: Progress, problems, prospects. Nat Med. 1997, 3 (6): 612-613. 10.1038/nm0697-612.PubMedGoogle Scholar
  20. Niidome T, Huang L: Gene therapy progress and prospects: nonviral vectors. Gene Ther. 2002, 9 (24): 1647-10.1038/ Scholar
  21. St George J: Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 2003, 10 (14): 1135-1141. 10.1038/ Scholar
  22. Flotte T: Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2004, 11 (10): 805-810. 10.1038/ Scholar
  23. Sinn P, Sauter S, McCray P: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 2005, 12 (14): 1089-1098. 10.1038/ Scholar
  24. Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP: Adeno-associated virus for cancer gene therapy. Cancer Res. 2001, 61 (17): 6313-PubMedGoogle Scholar
  25. Li C, Bowles DE, Van Dyke T, Samulski RJ: Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005, 12 (12): 913-925. 10.1038/sj.cgt.7700876.PubMedPubMed CentralGoogle Scholar
  26. Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE, Meleth S: Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 2004, 64 (5): 1781-1787. 10.1158/0008-5472.CAN-03-1786.PubMedGoogle Scholar
  27. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan S: Adeno-Associated Virus-Mediated Delivery of a Mutant Endostatin in Combination with Carboplatin Treatment Inhibits Orthotopic Growth of Ovarian Cancer and Improves Long-term Survival. Cancer Res. 2006, 66 (8): 4319-10.1158/0008-5472.CAN-05-3297.PubMedGoogle Scholar
  28. Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D, Chiorini JA: Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycan-independent transduction activity. J Virol. 2008, 82 (3): 1399-10.1128/JVI.02012-07.PubMedGoogle Scholar
  29. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM: Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004, 78 (12): 6381-10.1128/JVI.78.12.6381-6388.2004.PubMedPubMed CentralGoogle Scholar
  30. Mori S, Wang L, Takeuchi T, Kanda T: Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology. 2004, 330 (2): 375-383. 10.1016/j.virol.2004.10.012.PubMedGoogle Scholar
  31. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K: Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther. 2003, 14 (11): 1079-1088. 10.1089/104303403322124792.PubMedGoogle Scholar
  32. McCarty D, DiRosario J, Gulaid K, Muenzer J, Fu H: Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther. 2009, 16 (11): 1340-1352. 10.1038/gt.2009.85.PubMedPubMed CentralGoogle Scholar
  33. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973, 52 (11): 2745-10.1172/JCI107470.PubMedPubMed CentralGoogle Scholar
  34. Wu X, Dong X, Wu Z, Cao H, Niu D, Qu J, Wang H, Hou Y: A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chin Sci Bull. 2001, 46 (6): 485-488. 10.1007/BF03187263.Google Scholar
  35. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y: SKLB1002, A Novel Potent Inhibitor of Vascular Endothelial Growth Factor Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth in Vivo. Clin Canc Res. 2011, 17 (13): 4439-10.1158/1078-0432.CCR-10-3109.Google Scholar
  36. Liu J, Wei Y, Yang L, Zhao X, Tian L, Hou J, Niu T, Liu F, Jiang Y, Hu B: Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood. 2003, 102 (5): 1815-10.1182/blood-2002-12-3772.PubMedGoogle Scholar
  37. Ben-Sasson SA, Sherman Y, Gavrieli Y: Identification of dying cells-in situ staining. Methods Cell Biol. 1995, 46: 29-39.PubMedGoogle Scholar
  38. Shaheen R, Ahmad S, Liu W, Reinmuth N, Jung Y, Tseng W, Drazan K, Bucana C, Hicklin D, Ellis L: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001, 85 (4): 584-10.1054/bjoc.2001.1936.PubMedPubMed CentralGoogle Scholar
  39. Endo T, Toda M, Watanabe M, Iizuka Y, Kubota T, Kitajima M, Kawakami Y: In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther. 2002, 9 (2): 142-148. 10.1038/sj.cgt.7700407.PubMedGoogle Scholar
  40. Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG, Yang JL, Jiang SS, Wu Y, Yang L, Guan YS: Gene Therapy with the Angiogenesis Inhibitor Endostatin in an Orthotopic Lung Cancer Murine Model. Hum Gene Ther. 2009, 20 (2): 103-111. 10.1089/hum.2008.098.PubMedGoogle Scholar
  41. Samulski RJ, Berns KI, Tan M, Muzyczka N: Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci. 1982, 79 (6): 2077-10.1073/pnas.79.6.2077.PubMedPubMed CentralGoogle Scholar
  42. Wu Z, Asokan A, Samulski RJ: Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006, 14 (3): 316-327. 10.1016/j.ymthe.2006.05.009.PubMedGoogle Scholar
  43. Mingozzi F, High KA: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011, 12 (5): 341-355. 10.1038/nrg2988.PubMedGoogle Scholar
  44. Georg-Fries B, Biederlack S, Wolf J, Zur Hausen H: Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology. 1984, 134 (1): 64-71. 10.1016/0042-6822(84)90272-1.PubMedGoogle Scholar
  45. Erles K, Sebökovà P, Schlehofer JR: Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999, 59 (3): 406-411. 10.1002/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N.PubMedGoogle Scholar
  46. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:


© Wu et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.